drugset / Trial / NCT07816237
A Multicenter, Randomized, Open-Label, Positive Controlled Phase III Study to Evaluate the Efficacy and Safety of VSA012 Injection in Participants With Paroxysmal Nocturnal Hemoglobinuria Who Are Naive to Complement Inhibitor Therapy
RandomizedParallel-groupOpen-labelTreatment
Summary
A study of the efficacy and safety of VSA012 Injection compared to eculizumab for 24 weeks in patients with PNH.
Timeline
- Start
- 2026-10-29
- Primary completion
- 2027-09-30
- Completion
- 2029-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Eculizumab | Monoclonal antibody | — | — |
| Subject | VSA012 | Unknown | — | — |